Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Surface Oncology Inc. logo — #lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #Bo...

Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Founded 2014 United States Cambridge, United States 14 employees Post-IPO Equity Total: $88.90M Biotechnology, Health Care +1

General Information

Company Name Surface Oncology Inc.
Founded Year 2014
Location United States Cambridge, United States
Employees 14
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Surface Oncology Inc.. To contact Surface Oncology Inc., visit surfaceoncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Surface Oncology Inc. compare?

A PDF of Surface Oncology Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Surface Oncology Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Surface Oncology Inc.

Surface Oncology Inc. is a clinical-stage immuno-oncology company that was founded in 2014. The company is headquartered in the United States and has recently received a significant $28.90MPost-IPO Equity investment on 20 May 2020 from BVF Partners, EcoR1 Capital, Venrock Healthcare Capital Partners, RS Investments. Surface Oncology is dedicated to leveraging its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) to develop next-generation therapies for cancer patients. The company's focus on the development of a broader, more multi-faceted therapeutic approach represents a significant leap forward in immuno-oncology research. The company's diverse clinical and preclinical pipeline of immune-enhancing antibody candidates targets the innate and adaptive arms of the immune system. This approach is aimed at delivering dramatically different therapies for patients and their families by addressing the limitations of current first-generation immunotherapies. Surface Oncology aims to convert patients’ non-responsive ‘cold’ tumors into immune-active ones by leveraging its deep understanding of TME biology to target factors and cells that suppress the anti-tumor immune response. The company's emphasis on breaking through across all dimensions of its work reflects its commitment to delivering transformative outcomes for cancer patients. In terms of discovery, Surface Oncology utilizes its world-class Scientific Advisory Board (SAB) to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies. This approach generates therapeutic-quality antibodies and unique tools for exploring the biology of the tumor microenvironment. With its strong focus on addressing the limitations of current immunotherapies and a commitment to pushing the boundaries of immuno-oncology research, Surface Oncology is well-positioned to make a significant impact in the treatment of cancer.

Business keywords: immuno-oncology, cancer therapy, TME biology, immune system, antibody candidates, cancer research, novel immunotherapy targets, tumor microenvironment, immune evasion, biological pathways, clinical-stage, cancer treatments, scientific founders, biological research

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $28.90M 4
EcoR1 Capital Venrock Healthcare Capital Partners
EcoR1 Capital, Venrock Healthcare Capital Partners +2
20 May 2020
Debt Financing $25.00M 1
K2 HealthVentures
K2 HealthVentures
25 Nov 2019
Series A $35.00M 5
New Enterprise Associates Amgen Ventures Atlas Venture
New Enterprise Associates, Amgen Ventures +3
08 Jan 2015
Seed Round Undisclosed -
01 Sep 2014

Surface Oncology Inc. Alternatives & Competitors

View All Alternatives
Surface Oncology Inc. vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology
Surface Oncology Inc. vs
NextCure, Inc.
NextCure, Inc. United States

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel...

Post-IPO Equity
49 employees
Biopharma, Biotechnology
Compare Surface Oncology Inc. vs NextCure, Inc.
Surface Oncology Inc. vs
iTeos Therapeutics
iTeos Therapeutics United States

Cancer Immunotherapies by Design

Post-IPO Equity
186 employees
Biotechnology, Health Care
Compare Surface Oncology Inc. vs iTeos Therapeutics
Also compare with: Surface Oncology Inc. vs Sensei Bio Sensei Bio Surface Oncology Inc. vs IO Biotech IO Biotech View all alternatives

FAQ About Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021
Surface Oncology Inc. was founded in 2014.
Surface Oncology Inc. is headquartered in Cambridge, United States.
Surface Oncology Inc. operates in Biotechnology, Health Care and Life Sciences. Its work centres on immuno-oncology, cancer therapy, TME biology and immune system.
Surface Oncology Inc. has approximately 14 employees.
Surface Oncology Inc. has completed 4 funding rounds, raising a total of $88.90M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Surface Oncology Inc. include OncoResponse, NextCure, Inc., iTeos Therapeutics, TME Pharma, ImmunoGenesis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Surface Oncology Inc. and OncoResponse are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Surface Oncology Inc., https://bouncewatch.com/company/surface-oncology-inc, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout